Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10653753-B2
Publication Date
2020-05-19
Expiration Date
Abstract
In one aspect, methods of treating hyperinsulinemic hypoglycemia comprising administration of an effective amount of a derivative of an exendin-4 peptide are provided. In some embodiments, the method comprises subcutaneously administering to a patient having hyperinsulinemic hypoglycemia a therapeutically effective amount of exendin(5-39).
Core Innovation
The disclosed method addresses treatment of hyperinsulinemic hypoglycemia by administering an exendin-4 derivative selected from exendin(3-39), exendin(4-39), exendin(5-39), exendin(6-39), exendin(7-39), and exendin(8-39). The description also identifies exendin(5-39) and pegylated exendin(5-39) among the discussed derivatives and describes treatment in patients in need thereof.
The provided content reports that tested exendin(5-39), pegylated exendin(5-39), exendin(9-39), and pegylated exendin(9-39) show no agonist activity; unpegylated exendin(5-39) shows antagonist activity comparable to exendin(9-39), while the tested pegylated peptides show no significant antagonist activity. The background section is not included in the provided content, so the specific problem it identifies is not explicitly described.
Claims Coverage
The provided relevant claims identify one independent claim covering a method of treating hyperinsulinemic hypoglycemia.
Treatment using specified exendin-4 derivatives
The method administers an exendin-4 derivative to a patient in need thereof, selected from exendin(3-39), exendin(4-39), exendin(5-39), exendin(6-39), exendin(7-39), and exendin(8-39). The claim also recites a dose [procedural detail omitted for safety].
The independent claim centers on treating hyperinsulinemic hypoglycemia by administering one of six specified exendin-4 derivatives.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment of hyperinsulinemic hypoglycemia, including post-bariatric and other gastrointestinal-surgery-associated hyperinsulinemic hypoglycemia, and congenital hyperinsulinemic hypoglycemia.
Interested in licensing this patent?